Exploring the Role of Biosimilars in Optimizing Treatment of Retinal Diseases

Biosimilars: Health Economic Aspects

David Brown, MD

Show Description +

David Brown, MD, addresses the elephant in the room: what do biosimilars mean for the bottom line?

Posted: 4/14/2023

Keywords:

biosimilars

•

Biogen

Up Next

Name: Biosimilars: Health Economic Aspects
Uploaded: 2023-04-14T21:15:57+00:00
Description: David Brown, MD, addresses the elephant in the room: what do biosimilars mean for the bottom line?

Biosimilars: Learning from Other Parts of Medicine

Diana Do, MD

What Does the Conversation Sound Like?

David Brown, MD

The Current Treatment Paradigm in nAMD

Diana Do, MD

Undertreatment of nAMD and Implications for LongTerm Vision

David Brown, MD; Diana Do, MD; Peter Kaiser, MD; Neal Bressler, MD

What Is a Biosimilar?

Peter Kaiser, MD

Biosimilars: Impact on Cost

Peter Kaiser, MD

Understanding Biosimilar Clinical Trials

Peter Kaiser, MD

Ranibizumab-nuna: Review of Clinical Trial Data

Neil Bressler, MD

A Deeper Look at Clinical Trial Outcomes

David Brown, MD; Diana Do, MD; Peter Kaiser, MD; Neal Bressler, MD

Adopting Bioimilars: Practical Considerations

David Brown, MD

Back to All Videos

Biosimilars: Health Economic Aspects

David Brown, MD

David Brown, MD, addresses the elephant in the room: what do biosimilars mean for the bottom line?

Posted: 4/14/2023

Keywords:

biosimilars

•

Biogen

Resources

Biosimilars in Retinal Disease Management

View Resource

About Biogen

One of the world’s first global biotechnology companies, Biogen, was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Biogen is commercializing biosimilars and transforming the standard of care for patients in several areas of high unmet need.

Follow Biogen